Please check your email for the verification action. You may continue to use the site and you are now logged in, but you will not be able to return to the site in future until you confirm your email address.
Objectives. Salubrinal is a synthetic agent that elevates phosphorylation
of eukaryotic translation initiation factor 2 alpha (eIF2α) and
alleviates stress to the endoplasmic reticulum. Previously, we reported
that in chondrocytes, Salubrinal attenuates expression and activity
of matrix metalloproteinase 13 (MMP13) through downregulating nuclear
factor kappa B (NFκB) signalling. We herein examine whether Salubrinal
prevents the degradation of articular cartilage in a mouse model
of osteoarthritis (OA). Methods. OA was surgically induced in the left knee of female mice. Animal
groups included age-matched sham control, OA placebo, and OA treated
with Salubrinal or Guanabenz. Three weeks after the induction of
OA, immunoblotting was performed for NFκB p65 and p-NFκB p65. At
three and six weeks, the femora and tibiae were isolated and the sagittal
sections were stained with Safranin O. Results. Salubrinal suppressed the progression of OA by downregulating
p-NFκB p65 and MMP13. Although Guanabenz elevates the phosphorylation
level of eIF2α, it did not suppress the progression of OA. Conclusions. Administration of Salubrinal has chondroprotective effects in
arthritic joints. Salubrinal can be considered as a potential therapeutic
agent for alleviating symptoms of OA. Cite this article: Bone Joint Res 2015;4:84–92